Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance

Lenvatinib is a multitargeted tyrosine kinase inhibitor (TKI) that shows improved median progression-free survival (PFS) in patients with thyroid carcinomas. However, virtually all patients ultimately progress, indicating the need for a better understanding of the mechanisms of resistance. Here, we...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Int J Mol Sci
Asıl Yazarlar: Khan, Husain Yar, Ge, James, Nagasaka, Misako, Aboukameel, Amro, Mpilla, Gabriel, Muqbil, Irfana, Szlaczky, Mark, Chaker, Mahmoud, Baloglu, Erkan, Landesman, Yosef, Mohammad, Ramzi M., Azmi, Asfar S., Sukari, Ammar
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6982268/
https://ncbi.nlm.nih.gov/pubmed/31905765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21010237
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller